4.6 Article

Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and 15O-water positron emission tomography blood flow in breast cancer

期刊

ACADEMIC RADIOLOGY
卷 15, 期 10, 页码 1246-1254

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.acra.2008.03.019

关键词

breast cancers; MRI; enhancement kinetics; O-15-PET

资金

  1. National Institutes of Health [CA72064, CA42045]
  2. Fred Hutchinson Cancer Research Center Cancer Center [015704]

向作者/读者索取更多资源

Rationale and Objectives. We sought to (1) describe associations between measures of tumor perfusion by dynamic contrast-enhanced breast magnetic resonance imaging (DCE-MRI), blood flow by O-15-water positron emission tomography (PET) and metabolism by F-18-fluorodeoxyglucose (F-18)-FDG PET and (2) improve our understanding of tumor enhancement on MRI through independent measures of tumor metabolism and blood flow. Materials and Methods. We performed a retrospective analysis of the existing PET and MRI databases from the Departments of Nuclear Medicine and Radiology. We identified patients with locally advanced breast cancer who underwent O-15-water/F-18-FDG PET within 1 month of clinical DCE-MRI between February 2004 and August 2006. The O-15-water PET blood flow and F-18-FDG metabolic rate and tissue transport constant (K-1) in the primary malignancy were calculated. DCE-MRI peak percent enhancement and peak signal enhancement ratio (SER) were measured for each tumor. Correlations and regression analysis of these variables were performed. Results. Fifteen patients with complete PET and DCE-MRI data were included in the analysis cohort. Peak SER correlated significantly with blood flow (r = 0.73. P = .002) and K-1 (r = 0.76, P = .001). However, peak SER did not correlate significantly with FDG metabolic rate (r = 0.44. P = .101). There were no significant correlations between peak percent enhancement and any of the PET parameters. Conclusions. Our findings suggest that tumor perfusion. represented by O-15-water PET blood flow, is an important factor in the MRI enhancement of locally advanced breast cancer. A lack of correlation of FDG metabolic rate with blood flow and DCE-MRI kinetics suggests that F-18-FDG PET provides complementary metabolic information independent of vascular factors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted 18F-Fluorthanatrace PET Images of Ovarian Cancer

Anthony J. Young, Austin R. Pantel, Varsha Viswanath, Tiffany L. Dominguez, Mehran Makvandi, Hsiaoju Lee, Shihong Li, Erin K. Schubert, Daniel A. Pryma, Michael D. Farwell, Robert H. Mach, Fiona Simpkins, Lilie L. Lin, David A. Mankoff, Robert K. Doot

Summary: The PARP family of proteins is involved in various functions, including the DNA damage response. PARP inhibitors have shown therapeutic efficacy in cancer treatment, and F-18-fluorthanatrace uptake can serve as a biomarker for response to PARP inhibitor therapy. SUVmax and SUVpeak are robust measures of PARP-1 binding.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Principles of Tracer Kinetic Analysis in Oncology, Part II :Examples and Future Directions

Austin R. Pantel, Varsha Viswanath, Mark Muzi, Robert K. Doot, David A. Mankoff

Summary: Kinetic analysis in dynamic PET imaging allows estimation of biologic processes related to disease, going beyond static uptake measures. This two-part continuing education paper reviews principles and methodology of kinetic modeling in part I and showcases benefits of kinetic modeling in oncologic imaging through case examples in part II.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Principles of Tracer Kinetic Analysis in Oncology, Part I Principles and Overview of Methodology

Austin R. Pantel, Varsha Viswanath, Mark Muzi, Robert K. Doot, David A. Mankoff

Summary: PET enables noninvasive imaging of regional in vivo cancer biology. By engineering a radiotracer to target specific biologic processes of relevance to cancer (e.g., cancer metabolism, blood flow, proliferation, and tumor receptor expression or ligand binding), PET can detect cancer spread, characterize the cancer phenotype, and assess its response to treatment. However, static imaging at a single time point may not utilize all the information that PET cancer imaging can provide, and reliance on static imaging measures alone may lead to misleading results. This review introduces the principles and examples of kinetic analysis for oncologic PET imaging, highlighting the added benefits over static imaging.

JOURNAL OF NUCLEAR MEDICINE (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer

Hwan Lee, Joshua S. Scheuermann, Anthony J. Young, Robert K. Doot, Margaret E. Daube-Witherspoon, Erin K. Schubert, Matthew A. Fillare, David Alexoff, Joel S. Karp, Hank F. Kung, Daniel A. Pryma

Summary: In this pilot study, Ga-68-P16-093 showed superior diagnostic performance compared to conventional imaging methods for prostate cancer, leading to changes in patient management. Further investigation in larger clinical studies is warranted to explore its potential.

MOLECULAR IMAGING AND BIOLOGY (2022)

Review Radiology, Nuclear Medicine & Medical Imaging

Radiomic Analysis: Study Design, Statistical Analysis, and Other Bias Mitigation Strategies

Chaya S. Moskowitz, Mattea L. Welch, Michael A. Jacobs, Brenda F. Kurland, Amber L. Simpson

Summary: This article reviews common issues in radiomic research, with a focus on study design and statistical analysis considerations, and proposes approaches to avoid these pitfalls.

RADIOLOGY (2022)

Review Oncology

The Fundamental Flaws of the CNBSS Trials: A Scientific Review

Jean M. Seely, Peter R. Eby, Martin J. Yaffe

Summary: The negative findings of the Canadian National Breast Screening Study (CNBSS) trials, conducted 40 years ago, continue to heavily impact screening policies worldwide. This review highlights the flaws of the CNBSS trials, including inadequate power, poor quality mammography, inclusion of symptomatic women, and a study design allowing for randomization violation. These trials failed to demonstrate the mortality benefit of screening mammography, making them outliers among eight screening mammography RCTs.

JOURNAL OF BREAST IMAGING (2022)

Article Oncology

Errors in Conduct of the CNBSS Trials of Breast Cancer Screening Observed by Research Personnel

Jean M. Seely, Peter R. Eby, Paula B. Gordon, Shushiela Appavoo, Martin J. Yaffe

Summary: This study investigates the reasons why the Canadian National Breast Screening Study (CNBSS) did not demonstrate a reduction in mortality with mammography. It reveals concerns related to the validity of the randomization process, methods of recruiting women for the trials, and the training of CNBSS staff. Interviews with former CNBSS personnel confirm the presence of systematic recruitment of women with preexisting breast cancer symptoms, inadequate training and experience of the screening personnel, substandard imaging equipment, poor quality of mammography images, and reluctance of surgeons to perform biopsies or surgeries for women with suspicious abnormalities found only on screening mammography. These accounts highlight the inadequacy of CNBSS in assessing the efficacy of screening mammography and emphasize the need to consider the evidence from other randomized trials.

JOURNAL OF BREAST IMAGING (2022)

Article Oncology

The Benefits of Early Detection: Evidence From Modern International Mammography Service Screening Programs

Peter R. Eby, Sujata Ghate, Regina Hooley

Summary: Research confirms that regular screening with mammography significantly reduces breast cancer mortality, but the efficacy of screening remains a subject of debate. Recent studies utilize observational data and study designs to address these debates and inform the construction of effective databases for continuous assessment of optimal screening techniques in the current era of rapid medical technology advancement.

JOURNAL OF BREAST IMAGING (2022)

Article Cell Biology

[18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson's Disease

Robert K. Doot, Anthony J. Young, Ilya M. Nasrallah, Reagan R. Wetherill, Andrew Siderowf, Robert H. Mach, Jacob G. Dubroff

Summary: Neuroinflammation is an important factor in neurodegenerative diseases and is mediated by microglia. This study used [F-18]NOS PET imaging to measure neuroinflammation in idiopathic Parkinson's disease patients and found increased oxidative stress as a marker of inflammation in early-stage disease.
Editorial Material Public, Environmental & Occupational Health

Including the method of detection for breast cancer in the Surveillance, Epidemiology, and End Results database is long overdue

Daniel B. Kopans, Richard E. Sharpe Jr, Peter R. Eby

Summary: Debates on breast cancer screening have continued due to the lack of data on the method of detection and its impact on the decline in breast cancer deaths.

JOURNAL OF MEDICAL SCREENING (2023)

Meeting Abstract Neurosciences

A Single-Dose of Ketone Ester Decreases Brain Glucose Metabolism in Alcohol Use Disorder

Corinde Wiers, Anthony Young, Juliana Byanyima, Xinyi Li, Robert Doot, Sianneh Vesslee, Rishika Reddy, Zhenhao Shi, Reagan Wetherill, Timothy Pond, Nora Volkow, Henry Kranzler, Jacob Dubroff

NEUROPSYCHOPHARMACOLOGY (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

18F-fluciclovine PET and multi-parametric MRI to distinguish pseudoprogression from tumor progression in post-treatment glioblastoma

Ali Nabavizadeh, Stephen Bagley, Robert Doot, Jeffrey B. Ware, Anthony Young, Satyam Ghodasara, Chao Zhao, Hannah Anderson, Erin Schubert, Fraser Henderson, Austin Pantel, H. Isaac Chen, John Y. K. Lee, Nduka M. Amankulor, Donald M. O'Rourke, Arati Desai, MacLean Nasrallah, Steven Brem

JOURNAL OF NUCLEAR MEDICINE (2022)

Meeting Abstract Radiology, Nuclear Medicine & Medical Imaging

PET imaging of PARP-inhibitor drug-target engagement predicts response in ovarian cancer in a pilot study

Austin Pantel, Mehran Makvandi, Hyoung Kim, Joanna Weeks, Drew Torigian, Nawar Latif, Lainie Martin, Janos Tanyi, Mark Morgan, Robert Doot, Lilie Lin, David Mankoff, Robert Mach, Fiona Simpkins

JOURNAL OF NUCLEAR MEDICINE (2022)

Meeting Abstract Oncology

DISTINGUISHING PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA: COMBINED USE OF 18F-FLUCICLOVINE PET AND MULTI-PARAMETRIC MRI

Ali Nabavizadeh, Stephen Bagley, Jeffrey B. Ware, Robert K. Doot, Anthony Young, Satyam Ghodasara, Chao Zhao, Hannah Anderson, Erin Schubert, Erica L. Carpenter, Jacob Till, Fraser Henderson, Austin R. Pantel, Isaac Chen, John Yk Lee, Nduka Amankulor, Donald O'Rourke, Arati Desai, MacLean Nasrallah, Steven Brem

NEURO-ONCOLOGY (2022)

Article Oncology

The Development of 18F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1

Hsiaoju S. Lee, Sally W. Schwarz, Erin K. Schubert, Delphine L. Chen, Robert K. Doot, Mehran Makvandi, Lilie L. Lin, Elizabeth S. McDonald, David A. Mankoff, Robert H. Mach

Summary: This article describes the development of F-18-FTT as a radiotracer for imaging PARP-1 expression levels in breast and ovarian cancer patients. It also discusses the preparation and submission of an exploratory investigational new drug application to the FDA and the need for a commercialization strategy to overcome financial barriers in multicenter clinical trials.

RADIOLOGY-IMAGING CANCER (2022)

暂无数据